Lv31
300 积分 2024-03-06 加入
Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study
2天前
已完结
The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development
7天前
已完结
A phase II trial of the pan‐HER inhibitor poziotinib, in patients with HER2‐positive metastatic breast cancer who had received at least two prior HER2‐directed regimens: results of the NOV120101‐203 trial
14天前
已完结
Poziotinib treatment in patients with HER2-positive advanced breast cancer who have received prior anti-HER2 regimens
14天前
已完结
Sacituzumab Govitecan: A Review in Unresectable or Metastatic HR+/HER2− Breast Cancer
16天前
已完结
TROP-2 directed antibody-drug conjugates (ADCs): The revolution of smart drug delivery in advanced non-small cell lung cancer (NSCLC)
16天前
已完结
HER2-Low Breast Cancer: a New Subtype?
16天前
已完结
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
1个月前
已完结
Phase 1b/2 study of penpulimab (AK105), an antiprogrammed cell death‐1 immunoglobulin G1 antibody, in advanced or metastatic solid tumors (AK105‐204)
1个月前
已完结
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study
1个月前
已完结
皖公网安备34019202002308
